Renal denervation is a catheter-based, minimally invasive treatment to treat hypertension. Radiofrequency ablation burns the neurons in the renal arteries; as a result, blood pressure is reduced, and nerve activity is decreased. This approach is typically used to get better results when pharmacological treatment doesn’t relieve symptoms. With the help of ultrasound or radiofrequency pulses, the nerves that line the renal artery wall are destroyed.
In 2021, the market value of the renal denervation market was USD 219.49 million, and by 2030 it will be worth USD 4743.13 million, expanding at a 40.7% CAGR during the forecast period.
The market expansion is due to the rising prevalence and incidence of hypertension and blood pressure, changing lifestyles, improved health infrastructure in emerging nations, and lower-cost renal denervation therapy. However, the strict regulatory framework for renal denervation devices and the discomfort and agony experienced by patients throughout the surgery impede market expansion.
Market Dynamics
Drivers
One of the main factors boosting market growth is the significant increase in the prevalence of lifestyle diseases like hypertension. The significant rise is due to an increase in the number of people who smoke and drink alcohol, an increase in unhealthy dietary patterns, a rise in sedentary and busy lifestyles, and a rising geriatric population. Another significant growth-inducing component is the RDN system’s benefits, such as quick healing, safety, time efficiency, and cost-effectiveness. Furthermore, the market is expanding due to the rising demand for minimally invasive (MI) surgery. The introduction of micro-infusion technology, improved healthcare infrastructure, increased research and development (R&D) activities, and increased regulatory systems approval files are all contributing to the market’s expansion.
Restraints
The availability of other advanced technologies, demanding regulatory body approvals, poor reimbursement, and a shortage of qualified healthcare personnel are impeding market expansion.
Opportunity
Furthermore, expanding utilization of Medtronic Symplicity Spyral renal denervation, EnligHTNTM, IberisTM, Vessix V2, ParadiseTM, and RENLANE will stimulate market growth in the coming years.
Market Segmentation
Technology Insights
On the basis of technology, the market is segmented into ultrasound, radiofrequency, and micro-infusion.
The ultrasound segment was the global market leader in 2021, with a significant revenue share. In a minimally invasive procedure, ultrasound-based renal denervation devices ablate nerves in the walls of the renal arteries. Interacting with nerve impulse transmission to and from the kidney lowers blood pressure. High-frequency sound waves from ultrasound energy evaporate neurons without direct contact with tissues, limiting renal artery injury. The segment’s growth would greatly accelerate using this technique since the renal artery would sustain less injury.
End-Use Insights
On the basis of end-user, the renal denervation market is segmented into specialty clinics, hospitals, and others.
The hospital segment held maximum position in the market in 2021. The government worldwide is investing heavily in developing several specialty hospitals to fight severe disorders, boosting this segment’s growth.
Regional Analysis
In 2021, Asia Pacific ruled the entire market with a significant revenue share. There are many potential growth opportunities for the Asian-Pacific market players because of the region’s high prevalence of resistant hypertension, numerous unmet medical needs for hypertension treatment, increased awareness of cutting-edge technologies like renal denervation systems, and numerous untapped medical needs. Hence, the local market would experience significant growth during the ensuing years.
Key Players
- Abbott Laboratories
- Renal Dynamics Limited
- Ablative Solutions, Inc
- Cardiotonic Ltd
- Johnson & Johnson
- Boston Scientific Corporation
- Mercator MedSystems, Inc
- Medtronic plc
- ReCor Medical, Inc
- Terumo Corporation
In 2021, the market value of the renal denervation market was USD 219.49 million, and by 2030 it will be worth USD 4743.13 million, expanding at a 40.7% CAGR during the forecast period. One of the main drivers of market expansion is the large rise in the prevalence of lifestyle disorders like hypertension, which is caused by increased sedentary and stressful lifestyles, alcohol and tobacco use, poor eating habits, and an escalating senior population.
In 2013, as per the Habitats for Infectious prevention and Anticipation (CDC), over 3.6lakh individuals in the U.S. kicked the bucket as a result of hypertension. The event of hypertension has expanded from 17,307 for each 100,000 out of 1990 to 20,525 for every 100,000 out of 2015. Be that as it may, the renal denervation treatment has likewise shown a hopeful outcome in limiting hypertension. Thus, the benefits presented by such treatments, for example diminished treatment time, higher security, and long-lasting impacts are supporting the market development. Also, mechanical headway in renal denervation gadgets is probably going to drive the market.
In 2021, Europe drove the renal denervation market with regards to areas and is expected to keep up with the predominance in any event, during the figure time frame. North America renal denervation market is projected to follow Europe, with regards to income age, during the gauge time frame because of the rising number of filings for FDA endorsements in the U.S. Rising event of uncontrolled hypertension is likewise one of the key elements answerable for the North America renal denervation market development.
Accessibility of improved and elective innovation, like miniature mixture, for renal denervation frameworks and better medical services foundations in arising economies are additionally expected to upgrade market development. For example, Mercator MedSystem’s miniature implantation based renal denervation framework decreases the circulatory strain in patients, by conveying to its representatives at a particular site to denervate the renal vein.
A portion of the organizations in this market are Medtronic PLC; Cardiosonic, Inc.; Kona Clinical, Inc.; Abbott Research facilities; Ablative Arrangements, Inc.; Renal Elements; Mercator MedSystems, Inc.; ReCor Clinical, Inc.; Boston Logical Corp.; and Symple Careful, Inc. Different procedures, like Research and development, M&A, and item send off, are being embraced by these organizations to fortify their market position. For example, in August 2014, Kona Clinical started the WAVE IV clinical preliminary of its painless Encompass Sound Hypertension Treatment Framework. The organization reported that the path will treat 132 subjects at destinations in Australia, New Zealand, South America and, Europe.
Related Reports:
Soft Tissue Allografts Market Report – The global soft tissue allografts market will witness a robust CAGR of 4.72%, valued at $12.93 billion in 2021, expected to appreciate and reach $19.58 billion by 2030, confirms Strategic Market Research. North America led the industry with a total share of around 43.51 % in 2021.
